SlideShare a Scribd company logo
1 of 1
Download to read offline
More details available upon request (info@synapcon.com)
SynapCon – CEO/COO Sven Engel
Personal Profile
⁻ 10 years of experience in preclinical research (pharmacology, helminthology, molecular
biology, biotechnology, Hoechst AG)
⁻ 25 years of professional experience in clinical drug development (10 years Hoechst AG and its
successor companies - of which 5 years in international marketing with responsibility Asia -
Pacific, 15 years autonomously with global project responsibility)
⁻ A strong, resilient network to professional associations (German Biotech Cluster, Dechema),
organizations (House of Pharma), patients' associations (ACHSE e.V.), specialists (in different
common and rare indications, specific needs like data management and medical writing),
strong global partner network (orphan reach).
⁻ Superior exposure to authorities in Germany, Austria and Switzerland (PEI/BfArM,
Swissmedic).
Strengths and Competencies
⁻ Strong enforcement project management, team management and team building
⁻ Special competent employees and freelancers
⁻ Extensive experience in intercultural management of complex projects
⁻ Comprehensive technical and organizational know-how
Professional Experience
⁻ Clinical operations (phase II - IV) with specialization in the field of rare diseases (studies with
small patient population)
⁻ Feasibility studies (regardless of further study continuation) with attractive fixed price levels
⁻ Recent and extensive experience with non-interventional projects (close cooperation with
marketing and sales departments).
⁻ Regulatory (authorities, ethics) and negotiation (preparation) of contracts with institutions
(contracts with investigators)
Selected references
⁻ Lantus (Insulin)
⁻ Exubera (Inhalative Insulin)
⁻ Ketek (Antibiotic)
⁻ Firazyr (Icatibant – Bradikininantagonist)
⁻ Cefrome (Antibiotics)
⁻ Propentofylline (Dementia, Alzheimer and Vascular)
⁻ Amielderly (Psychoses)
⁻ Femara (Breast cancer)
⁻ Dermatology (Psoriasis, Skin atrophy, Mycosis)
⁻ Adipositas, Cardiovascular diseases
⁻ Hematologic disorders (e.g. Afibrinogenaemia, Neutropenia)
⁻ Further rare diseases (HAE, lysosomal storage disorders)
⁻ Paediatrics and neonatology

More Related Content

Similar to Short summary Sven Engel, CEO SynapCon

European Patients’ Academy on Therapeutic Innovation: Shifting paradigms in ...
European Patients’ Academy on Therapeutic Innovation:Shifting paradigms in ...European Patients’ Academy on Therapeutic Innovation:Shifting paradigms in ...
European Patients’ Academy on Therapeutic Innovation: Shifting paradigms in ...patvocates
 
2013 09 25_ildiko_innovation at teva
2013 09 25_ildiko_innovation at teva2013 09 25_ildiko_innovation at teva
2013 09 25_ildiko_innovation at tevainnovationday2013
 
R&D and Clinical trials at Gedeon Richter PLC.
R&D and Clinical trials at Gedeon Richter PLC.R&D and Clinical trials at Gedeon Richter PLC.
R&D and Clinical trials at Gedeon Richter PLC.Tristan Azbej, PhD
 
Il processo di innovazione in atto: dalle strategie di brevettazione al fundr...
Il processo di innovazione in atto: dalle strategie di brevettazione al fundr...Il processo di innovazione in atto: dalle strategie di brevettazione al fundr...
Il processo di innovazione in atto: dalle strategie di brevettazione al fundr...Sardegna Ricerche
 
European Patients Academy - Presentation of Jan Geissler at EPF AGM
European Patients Academy - Presentation of  Jan Geissler at EPF AGMEuropean Patients Academy - Presentation of  Jan Geissler at EPF AGM
European Patients Academy - Presentation of Jan Geissler at EPF AGMjangeissler
 
A snapshot of EUPATI: Why the educated patient is so vital to success in clin...
A snapshot of EUPATI: Why the educated patient is so vital to success in clin...A snapshot of EUPATI: Why the educated patient is so vital to success in clin...
A snapshot of EUPATI: Why the educated patient is so vital to success in clin...jangeissler
 
Changes in patient organisations - and how this changes the medical world
Changes in patient organisations - and how this changes the medical worldChanges in patient organisations - and how this changes the medical world
Changes in patient organisations - and how this changes the medical worldjangeissler
 
European Patients' Academy - Presentation at IMI Patient Focus Meeting on 12 ...
European Patients' Academy - Presentation at IMI Patient Focus Meeting on 12 ...European Patients' Academy - Presentation at IMI Patient Focus Meeting on 12 ...
European Patients' Academy - Presentation at IMI Patient Focus Meeting on 12 ...EUPATI
 
Don't just talk about patient centricity - put meaningful patient engagement ...
Don't just talk about patient centricity - put meaningful patient engagement ...Don't just talk about patient centricity - put meaningful patient engagement ...
Don't just talk about patient centricity - put meaningful patient engagement ...jangeissler
 
EUPATI Launch Meeting - Jan Geissler
EUPATI Launch Meeting - Jan GeisslerEUPATI Launch Meeting - Jan Geissler
EUPATI Launch Meeting - Jan Geisslerjangeissler
 
Orphan Drugs Summit 2015
Orphan Drugs Summit 2015Orphan Drugs Summit 2015
Orphan Drugs Summit 2015Copperberg
 
Changes in patient organisations - and how this changes the medical world
Changes in patient organisations - and how this changes the medical worldChanges in patient organisations - and how this changes the medical world
Changes in patient organisations - and how this changes the medical worldjangeissler
 
10-3. Rare disease registries. Samantha Parker (eng)
10-3. Rare disease registries. Samantha Parker (eng)10-3. Rare disease registries. Samantha Parker (eng)
10-3. Rare disease registries. Samantha Parker (eng)KidneyOrgRu
 

Similar to Short summary Sven Engel, CEO SynapCon (20)

CV TRAN CHUNG THUY
CV TRAN CHUNG THUYCV TRAN CHUNG THUY
CV TRAN CHUNG THUY
 
Jm 2010.June Long Cv
Jm 2010.June Long CvJm 2010.June Long Cv
Jm 2010.June Long Cv
 
European Patients’ Academy on Therapeutic Innovation: Shifting paradigms in ...
European Patients’ Academy on Therapeutic Innovation:Shifting paradigms in ...European Patients’ Academy on Therapeutic Innovation:Shifting paradigms in ...
European Patients’ Academy on Therapeutic Innovation: Shifting paradigms in ...
 
2013 09 25_ildiko_innovation at teva
2013 09 25_ildiko_innovation at teva2013 09 25_ildiko_innovation at teva
2013 09 25_ildiko_innovation at teva
 
R&D and Clinical trials at Gedeon Richter PLC.
R&D and Clinical trials at Gedeon Richter PLC.R&D and Clinical trials at Gedeon Richter PLC.
R&D and Clinical trials at Gedeon Richter PLC.
 
Il processo di innovazione in atto: dalle strategie di brevettazione al fundr...
Il processo di innovazione in atto: dalle strategie di brevettazione al fundr...Il processo di innovazione in atto: dalle strategie di brevettazione al fundr...
Il processo di innovazione in atto: dalle strategie di brevettazione al fundr...
 
European Patients Academy - Presentation of Jan Geissler at EPF AGM
European Patients Academy - Presentation of  Jan Geissler at EPF AGMEuropean Patients Academy - Presentation of  Jan Geissler at EPF AGM
European Patients Academy - Presentation of Jan Geissler at EPF AGM
 
CV-Englisch new
CV-Englisch  newCV-Englisch  new
CV-Englisch new
 
A snapshot of EUPATI: Why the educated patient is so vital to success in clin...
A snapshot of EUPATI: Why the educated patient is so vital to success in clin...A snapshot of EUPATI: Why the educated patient is so vital to success in clin...
A snapshot of EUPATI: Why the educated patient is so vital to success in clin...
 
1_Resume JGoldberg
1_Resume JGoldberg1_Resume JGoldberg
1_Resume JGoldberg
 
Senior Fellow
Senior FellowSenior Fellow
Senior Fellow
 
Changes in patient organisations - and how this changes the medical world
Changes in patient organisations - and how this changes the medical worldChanges in patient organisations - and how this changes the medical world
Changes in patient organisations - and how this changes the medical world
 
European Patients' Academy - Presentation at IMI Patient Focus Meeting on 12 ...
European Patients' Academy - Presentation at IMI Patient Focus Meeting on 12 ...European Patients' Academy - Presentation at IMI Patient Focus Meeting on 12 ...
European Patients' Academy - Presentation at IMI Patient Focus Meeting on 12 ...
 
Don't just talk about patient centricity - put meaningful patient engagement ...
Don't just talk about patient centricity - put meaningful patient engagement ...Don't just talk about patient centricity - put meaningful patient engagement ...
Don't just talk about patient centricity - put meaningful patient engagement ...
 
EUPATI Launch Meeting - Jan Geissler
EUPATI Launch Meeting - Jan GeisslerEUPATI Launch Meeting - Jan Geissler
EUPATI Launch Meeting - Jan Geissler
 
Orphan Drugs Summit 2015
Orphan Drugs Summit 2015Orphan Drugs Summit 2015
Orphan Drugs Summit 2015
 
Vigilance 2018 final
Vigilance 2018 finalVigilance 2018 final
Vigilance 2018 final
 
Changes in patient organisations - and how this changes the medical world
Changes in patient organisations - and how this changes the medical worldChanges in patient organisations - and how this changes the medical world
Changes in patient organisations - and how this changes the medical world
 
10-3. Rare disease registries. Samantha Parker (eng)
10-3. Rare disease registries. Samantha Parker (eng)10-3. Rare disease registries. Samantha Parker (eng)
10-3. Rare disease registries. Samantha Parker (eng)
 
CV - Rawad Abdayem
CV - Rawad AbdayemCV - Rawad Abdayem
CV - Rawad Abdayem
 

Short summary Sven Engel, CEO SynapCon

  • 1. More details available upon request (info@synapcon.com) SynapCon – CEO/COO Sven Engel Personal Profile ⁻ 10 years of experience in preclinical research (pharmacology, helminthology, molecular biology, biotechnology, Hoechst AG) ⁻ 25 years of professional experience in clinical drug development (10 years Hoechst AG and its successor companies - of which 5 years in international marketing with responsibility Asia - Pacific, 15 years autonomously with global project responsibility) ⁻ A strong, resilient network to professional associations (German Biotech Cluster, Dechema), organizations (House of Pharma), patients' associations (ACHSE e.V.), specialists (in different common and rare indications, specific needs like data management and medical writing), strong global partner network (orphan reach). ⁻ Superior exposure to authorities in Germany, Austria and Switzerland (PEI/BfArM, Swissmedic). Strengths and Competencies ⁻ Strong enforcement project management, team management and team building ⁻ Special competent employees and freelancers ⁻ Extensive experience in intercultural management of complex projects ⁻ Comprehensive technical and organizational know-how Professional Experience ⁻ Clinical operations (phase II - IV) with specialization in the field of rare diseases (studies with small patient population) ⁻ Feasibility studies (regardless of further study continuation) with attractive fixed price levels ⁻ Recent and extensive experience with non-interventional projects (close cooperation with marketing and sales departments). ⁻ Regulatory (authorities, ethics) and negotiation (preparation) of contracts with institutions (contracts with investigators) Selected references ⁻ Lantus (Insulin) ⁻ Exubera (Inhalative Insulin) ⁻ Ketek (Antibiotic) ⁻ Firazyr (Icatibant – Bradikininantagonist) ⁻ Cefrome (Antibiotics) ⁻ Propentofylline (Dementia, Alzheimer and Vascular) ⁻ Amielderly (Psychoses) ⁻ Femara (Breast cancer) ⁻ Dermatology (Psoriasis, Skin atrophy, Mycosis) ⁻ Adipositas, Cardiovascular diseases ⁻ Hematologic disorders (e.g. Afibrinogenaemia, Neutropenia) ⁻ Further rare diseases (HAE, lysosomal storage disorders) ⁻ Paediatrics and neonatology